Market Place
Sourcing Support
Evecxia Receives US Patent for EVX-301 in Suicidal Ideation
25 Nov 2024 //
BUSINESSWIRE
Evecxia Completes PreIND Meeting with FDA for EVX-101 in Depression
25 Oct 2024 //
BUSINESSWIRE
Evecxia Therapeutics ACCESS CHINA Partnering Forum
18 Sep 2024 //
BUSINESSWIRE
Evecxia Files Patent For 5-HTP Chemical Synthesis
23 Jul 2024 //
BUSINESSWIRE
Evecxia Therapeutics Appointed Allan L. Shaw and Elliot Ehrich
30 Oct 2023 //
BUSINESSWIRE
Evecxia Reports No Toxicology Findings in Nonclinical GLP Studies
02 Oct 2023 //
BUSINESSWIRE
Evecxia & Quotient Sciences Complete Ph I Milestone for New Depression Treatment
21 Sep 2023 //
PR NEWSWIRE
Evecxia Therapeutics Announces CEO Transition
14 Sep 2023 //
BUSINESSWIRE
Evecxia Therapeutics Announces Data Presentations on Lead Candidate EVX-101
25 May 2023 //
BUSINESSWIRE
Evecxia Receives Notice Of Allowance For A U.S. Patent Covering EVX?101
28 Apr 2023 //
BUSINESSWIRE
Evecxia Therapeutics Reports Favorable Data From a Phase 1 SAD/MAD Trial
10 Apr 2023 //
PRESS RELEASE
Evecxia Reports Favorable Data From a Phase 1 Trial of Adjunctive EVX-101
10 Apr 2023 //
BUSINESSWIRE
Evecxia Therapeutics Reports Favorable Data From a Phase 1 Trial of EVX-301
15 Mar 2023 //
BUSINESSWIRE
Evecxia Announces Leadership Transition to Support Next Phase of Development
13 Jun 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.